Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
Esophageal Cancer
Conditions: official terms
Esophageal Neoplasms
Conditions: Keywords
Endostar, Radiotherapy, Esophageal Cancer
Study Type
Study Phase
Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Endostar Type: Drug
Name: Radiotherapy Type: Radiation
Overall Status
This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histological or cytological diagnosis of previously untreated stage I-III esophageal cancer

- Measurable disease according to RECIST criteria

- ECOG Performance Status 0-1

- The length of esophageal carcinoma ≤ 10 cm

- Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L

- Renal function: Cr ≤ 2.0×UNL

- Hepatic function: BIL ≤ 2.0×UNL, ALT/AST ≤ 5.0×UNL

Exclusion Criteria:

- Pregnant or lactating women

- Evidence of bleeding diathesis, serious infection

- Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)

- Uncontrollable mental and nervous disorders
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China
Status: Recruiting
Contact: Xiaodong Jiang, MD - 0518-85605120
Start Date
May 2011
Completion Date
May 2013
Jiangsu Simcere Pharmaceutical Co., Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Record processing date processed this data on July 28, 2015 page